未登录

D

Daša Stupica

Department of Infectious Diseases

H指数:17

被引数:1,137

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The risk of hepatitis B virus reactivation in COVID-19 patients treated with corticosteroids: a retrospective observational cohort study

用糖皮质激素治疗的新型冠状病毒肺炎患者乙型肝炎病毒再激活的风险: 回顾性观察性队列研究

BMC Infectious Diseases

IF3

2026-01-200

OAAI

Which trial do we need? Corticosteroid therapy in Lyme borreliosis–associated facial palsy: a double-blind placebo-controlled multicentre randomized trial

我们需要哪个试验？皮脂醇疗法在莱姆疏螺旋体病相关面瘫中的应用：一项双盲安慰剂对照多中心随机试验

Clinical Microbiology and Infection

IF8.5

2025-11-130

PRE

Presentation, Management, and Outcome of Tick-Borne Encephalitis in Patients Referred to Infectious Diseases or Neurology

JOURNAL OF CLINICAL MEDICINE

IF2.9

2024-12-250

OAAI

Which trial do we need? Dexamethasone therapy in adults with tick-borne encephalitis: a double-blind placebo-controlled multicentre randomized trial

CLINICAL MICROBIOLOGY AND INFECTION

IF8.5

2024-11-010

PRE

Which trial do we need? Treatment of multiple erythema migrans with doxycycline for 7 days versus 14 days

CLINICAL MICROBIOLOGY AND INFECTION

IF8.5

2024-02-012

PRE

Which trial do we need? Mannitol therapy in hospitalized adult patients with tick-borne encephalitis and brain oedema: a double-blind placebo-controlled multicentre randomized trial

CLINICAL MICROBIOLOGY AND INFECTION

IF8.5

2023-12-012

PRE

Treatment of erythema migrans with doxycycline for 7 days versus 14 days in Slovenia: a randomised open-label non-inferiority trial

LANCET INFECTIOUS DISEASES

IF31

2023-03-019

PRE

SARS-CoV-2 Vaccination and Clinical Presentation of COVID-19 in Patients Hospitalized during the Delta- and Omicron-Predominant Periods

在三角洲和Omicron为主的时期住院患者的SARS-CoV-2疫苗接种和新型冠状病毒肺炎的临床表现

JOURNAL OF CLINICAL MEDICINE

IF2.9

2023-01-263

OAAI

The Impact of SARS-CoV-2 Primary Vaccination in a Cohort of Patients Hospitalized for Acute COVID-19 during Delta Variant Predominance

JOURNAL OF CLINICAL MEDICINE

IF2.9

2022-02-237

OA

Systemic immune responses in patients with early localized or early disseminated Borrelia afzelii lyme borreliosis

IMMUNITY INFLAMMATION AND DISEASE

IF2.7

2020-12-310

OAAI

Five-Day vs 10-Day Postexposure Chemoprophylaxis With Oseltamivir to Prevent Hospital Transmission of Influenza: A Noninferiority Randomized Open-Label Study

OPEN FORUM INFECTIOUS DISEASES

IF3.8

2020-06-194

OAAI

Antibiotic Use and Long-Term Outcome in Patients with Tick-Borne Encephalitis and Co-Infection with Borrelia Burgdorferi Sensu Lato in Central Europe. A Retrospective Cohort Study

JOURNAL OF CLINICAL MEDICINE

IF2.9

2019-10-207

OAAI

Clinical Course, Serologic Response, and Long-Term Outcome in Elderly Patients with Early Lyme Borreliosis

JOURNAL OF CLINICAL MEDICINE

IF2.9

2018-12-0222

OAAI

Comparison of Clinical Course and Treatment Outcome for Patients With Early Disseminated or Early Localized Lyme Borreliosis

JAMA DERMATOLOGY

IF11

2018-09-0127

OAAI

Doxycycline-induced photosensitivity in patients treated for erythema migrans

BMC INFECTIOUS DISEASES

IF3

2018-08-034

OAAI

The long-term outcome of tick-borne encephalitis in Central Europe

TICKS AND TICK-BORNE DISEASES

IF3.4

2018-02-0153

PREAI

Oral doxycycline versus intravenous ceftriaxone for treatment of multiple erythema migrans: an open-label alternate-treatment observational trial

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

IF3.6

2018-01-2923

OAAI

Pathogenetic implications of the age at time of diagnosis and skin location for acrodermatitis chronica atrophicans

TICKS AND TICK-BORNE DISEASES

IF3.4

2017-02-0111

PREAI

Course and Outcome of Early European Lyme Neuroborreliosis (Bannwarth Syndrome): Clinical and Laboratory Findings

CLINICAL INFECTIOUS DISEASES

IF7.3

2016-05-0894

OAAI

Differences in Genotype, Clinical Features, and Inflammatory Potential of Borrelia burgdorferi sensu stricto Strains from Europe and the United States

EMERGING INFECTIOUS DISEASES

IF6.6

2016-05-0178

OAAI